BioCentury
ARTICLE | Clinical News

ATX-101: Completed Phase III enrollment

September 10, 2012 7:00 AM UTC

Kythera completed enrollment of a total of more than 1,000 patients in the identical, double-blind, placebo-controlled, North American Phase III REFINE-1 and REFINE-2 trials evaluating 2 mg/cm 2 subcutaneous ATX-101 in 28-day cycles for up to 6 cycles. ...